These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 27908801)

  • 1. Managing immune checkpoint-inhibitor-induced severe autoimmune-like hepatitis by liver-directed topical steroids.
    Ziemer M; Koukoulioti E; Beyer S; Simon JC; Berg T
    J Hepatol; 2017 Mar; 66(3):657-659. PubMed ID: 27908801
    [No Abstract]   [Full Text] [Related]  

  • 2. Dramatic effect of nivolumab against melanoma and immune-related liver toxicity: A detailed histopathological and immunohistochemical analysis of nivolumab-induced liver toxicity.
    Namiki T; Nojima K; Chikazawa S; Iwamoto Y; Otsuki Y; Albusani H; Miura K; Kiyokawa Y; Asakage T; Yokozeki H
    J Dermatol; 2019 May; 46(5):e182-e183. PubMed ID: 30474878
    [No Abstract]   [Full Text] [Related]  

  • 3. Autoimmune Polyarthritis Induced by Cancer Immunotherapy With Checkpoint Inhibitor.
    Quresh Q; Quinet R
    J Clin Rheumatol; 2017 Jun; 23(4):235. PubMed ID: 28538282
    [No Abstract]   [Full Text] [Related]  

  • 4. Pembrolizumab-Induced Liver Injury: Beyond Immune-Mediated Hepatitis.
    Herms Q; Fuster-Anglada C; Juanola A
    Gastroenterology; 2024 Aug; 167(3):443-445. PubMed ID: 38320724
    [No Abstract]   [Full Text] [Related]  

  • 5. Pembrolizumab as a Cause of Cholangiopathy in a Patient With Metastatic Melanoma.
    Stuart L; Lambourne B; Turner P; Jones DEJ; Plummer R; Cresti N; Dyson JK
    Hepatology; 2020 Jun; 71(6):2164-2166. PubMed ID: 31872447
    [No Abstract]   [Full Text] [Related]  

  • 6. Hepatobiliary and Pancreatic: Biliary injury related to checkpoint inhibitor "pembrolizumab".
    Kida A; Matsuda K; Matsuda M; Sakai A
    J Gastroenterol Hepatol; 2019 Sep; 34(9):1478. PubMed ID: 31197882
    [No Abstract]   [Full Text] [Related]  

  • 7. Late-Onset Fulminant Myocarditis With Immune Checkpoint Inhibitor Nivolumab.
    Yamaguchi S; Morimoto R; Okumura T; Yamashita Y; Haga T; Kuwayama T; Yokoi T; Hiraiwa H; Kondo T; Sugiura Y; Watanabe N; Kano N; Kohno K; Fukaya K; Sawamura A; Yokota K; Ishii H; Nakaguro M; Akiyama M; Murohara T
    Can J Cardiol; 2018 Jun; 34(6):812.e1-812.e3. PubMed ID: 29801747
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Are we over-treating with checkpoint inhibitors?
    Danson S; Hook J; Marshall H; Smith A; Bell S; Rodwell S; Corrie P
    Br J Cancer; 2019 Oct; 121(8):629-630. PubMed ID: 31527686
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Personalized Dosing Versus Fixed Dosing of Immune Checkpoint Inhibitors: A Cost Analysis Study.
    Mukherjee S; Ibrahimi S; Machiorlatti M; Roman D; Saleem R; Hassan A; Baxley A; Vesely S; Aljumaily R
    Am J Ther; 2018; 25(6):e767-e768. PubMed ID: 29746291
    [No Abstract]   [Full Text] [Related]  

  • 10. Angioedema late in the course of adjuvant nivolumab therapy for melanoma.
    Ratra A; Dasanu CA
    J Oncol Pharm Pract; 2020 Jun; 26(4):1019-1021. PubMed ID: 31635547
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increased risk of immune checkpoint inhibitor-induced type 1 diabetes mellitus with the new approved 6-week scheme of pembrolizumab in patients with melanoma?
    Kähler KC; Kosova K; Bohne AS; Schreiber S; Hauschild A
    Eur J Cancer; 2020 Oct; 138():169-171. PubMed ID: 32890812
    [No Abstract]   [Full Text] [Related]  

  • 12. Non-alcoholic fatty liver disease is a potential risk factor for liver injury caused by immune checkpoint inhibitor.
    Sawada K; Hayashi H; Nakajima S; Hasebe T; Fujiya M; Okumura T
    J Gastroenterol Hepatol; 2020 Jun; 35(6):1042-1048. PubMed ID: 31752049
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immune checkpoint inhibitor-induced lymphocytic fasciitis.
    Rischin A; Brady B; McLean C; Ostor AJK
    Intern Med J; 2018 Dec; 48(12):1550-1552. PubMed ID: 30517989
    [No Abstract]   [Full Text] [Related]  

  • 14. Balancing the Checkpoint: Managing Colitis Associated with Dual Checkpoint Inhibitors and High-Dose Aspirin.
    Hammami MB; Gill R; Thiruvengadam N; Oh DY; Beck K; Mahadevan U; Kattah MG
    Dig Dis Sci; 2019 Mar; 64(3):685-688. PubMed ID: 30778872
    [No Abstract]   [Full Text] [Related]  

  • 15. Case of type 1 diabetes associated with less-dose nivolumab therapy in a melanoma patient.
    Teramoto Y; Nakamura Y; Asami Y; Imamura T; Takahira S; Nemoto M; Sakai G; Shimada A; Noda M; Yamamoto A
    J Dermatol; 2017 May; 44(5):605-606. PubMed ID: 27334247
    [No Abstract]   [Full Text] [Related]  

  • 16. Immune checkpoint inhibitor therapy and myocarditis: a systematic review of reported cases.
    Atallah-Yunes SA; Kadado AJ; Kaufman GP; Hernandez-Montfort J
    J Cancer Res Clin Oncol; 2019 Jun; 145(6):1527-1557. PubMed ID: 31028541
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Autoimmune Effects of Lung Cancer Immunotherapy Revealed by Data-Driven Analysis on a Nationwide Cohort.
    Yang S; Yu KH; Palmer N; Fox K; Kou SC; Kohane IS
    Clin Pharmacol Ther; 2020 Feb; 107(2):388-396. PubMed ID: 31356677
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Pembrolizumab for the treatment of melanoma: updates and perspectives.].
    Chiarion Sileni V; Mandalà M; Queirolo P
    Recenti Prog Med; 2017 Dec; 108(12):528-531. PubMed ID: 29297903
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Case of acute-onset type 1 diabetes induced by long-term immunotherapy with nivolumab in a patient with mucosal melanoma.
    Maekawa T; Okada K; Okada H; Kado S; Kamiya K; Komine M; Murata S; Oka K; Ishibashi S; Ohtsuki M
    J Dermatol; 2019 Dec; 46(12):e463-e464. PubMed ID: 31436330
    [No Abstract]   [Full Text] [Related]  

  • 20. Checkpoint Inhibitors May Cause Pseudoprogression and Dose-Limiting Side Effects.
    Wiley K
    ONS Connect; 2016 Jul; 31(7):24. PubMed ID: 30549937
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.